(Galliprant's) sitting stagnant on shelves at the price point they have it at right now.
Sam,
Would appreciate it if you explain this more.
I certainly don't mean to be argumentative but we had two german shepherds die painful deaths, especially the second beautiful full-blooded shepherd who died a particularly heart-rending death from osteoarthritis.
My wife got a more expensive, dangerous drug from our vet for our severely crippled, youngish border collie/labrador mix that helped somewhat like drugs in the past but it doesn't begin to compare with the maintenance doses of Galliprant that I got only with considerable trouble in our rural area.
I am having trouble being sure of the name of the first drug.
As a maintenance drug, Galliprant is more expensive than a short time fix.
Again Galliprant [a prostaglandin is not properly called an NSAID since it is both an anti-inflammatory and promoter of inflammation to fight disease. I suspect such a complexity was the reason prostaglandin sat on the laboratory shelves for a decade ot two without trials and why Eli Lilly chose PETX to experiment with the drug for dogs instead of its own veterinary subsidiary.
Contrary opinions solicited because we realize the risk inherent in using a newly approved powerfu drug with a skimpy safety trial.
If Galliprant was selling as well as it was being touted to they should have money rolling in.
Again I consider myself at a great disadvantage questioning a veterinarian's expert opinion but ramp up of human drug sales in America is very slow because of such as advertising wars that appears unique to America. Hopefully the projected admission of Galliprant to marketing in Europe will result in quicker sales ramp up.
Best, Terry
